Home
World Journal of Advanced Research and Reviews
International Journal with High Impact Factor for fast publication of Research and Review articles

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

eISSN: 2581-9615 || CODEN: WJARAI || Impact Factor 8.2 ||  CrossRef DOI

Research and review articles are invited for publication in March 2026 (Volume 29, Issue 3) Submit manuscript

Identification of deactivation procedure for Trilaciclib

Breadcrumb

  • Home
  • Identification of deactivation procedure for Trilaciclib

Raghuveera Hathibelagal Goruva *, Anjaneyulu Vinukonda, Neelesh Chaubey and Harish Pandey

Department of pharmacy; Sri Satya Sai University of Technology and Medical Sciences, Sehore, India.
 
Research Article
World Journal of Advanced Research and Reviews, 2022, 15(03), 467-472
Article DOI: 10.30574/wjarr.2022.15.3.0972
DOI url: https://doi.org/10.30574/wjarr.2022.15.3.0972
 
Received on 25 August 2022; revised on 27 September 2022; accepted on 30 September 2022\
 
The Indian health-care facilities (HCFs) made some guidelines related to cytotoxic drugs so called cytotoxic policy for patient safety and health-care worker safety, and environmental monitoring program as per the available international guidelines. Trilaciclib is indicated for the treatment of patients with multiple myeloma and chemically it is a tetra peptide epoxy ketone and an analog of epoxomicin. Analytical method for the detection of Deactivating agent and concentration play an impartment role in the pharmaceuticals especially with cytotoxic molecules after completion of manufacturing and testing is mandatory to follow the safety protocol to dispose those materials. The present invention provides to identify the suitable deactivating agent for the neutralization of Trilaciclib injection 10 mg/mL and Trilaciclib API with respect to concentration and time. This method developed based by RP-HPLC.
 
Trilaciclib; Deactivating Agent; Sodium Hypochlorite Solution; Parenteral dosage form; RP-HPLC; Cytotoxic waste
 
https://wjarr.com/sites/default/files/fulltext_pdf/WJARR-2022-0972.pdf

Preview Article PDF

Raghuveera Hathibelagal Goruva, Anjaneyulu Vinukonda, Neelesh Chaubey and Harish Pandey. Identification of deactivation procedure for Trilaciclib. World Journal of Advanced Research and Reviews, 2022, 15(3), 467-472. Article DOI: https://doi.org/10.30574/wjarr.2022.15.3.0972

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.

All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 World Journal of Advanced Research and Reviews - All rights reserved

Developed & Designed by VS Infosolution